Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Overview
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Companies Involved in Therapeutics Development
KM Biologics Co Ltd
Lee’s Pharmaceutical Holdings Ltd
PlateletBio
Sanofi
TagCyx Biotechnologies
Takeda Pharmaceutical Co Ltd
TargED Biopharmaceuticals BV
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Drug Profiles
apadamtase alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
caplacizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Thrombotic Thrombocytopenic Purpura - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate ADAMTS13 for Thrombotic Thrombocytopenic Purpura - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Microlyse - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint ADAMTS-13 Replacement for Thrombotic Thrombocytopenic Purpura - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAGX-0004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZK-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Dormant Projects
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Discontinued Products
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Product Development Milestones
Featured News & Press Releases
Jun 10, 2021: Lee’s Pharm announces results of phase I clinical trial on the safety and antithrombotic efficacy of ANFIBATIDE
Sep 21, 2018: A Trojan Horse delivery of possible treatment for a rare, potentially deadly, blood-clotting disorder
Sep 14, 2017: Engineered Therapy for Blood Clotting Disorder Shows Early Promise
Mar 22, 2017: Shire receives FDA Fast Track desigtion for recombint ADAMTS13 (SHP655) for treatment of hereditary thrombotic thrombocytopenic purpura
May 25, 2016: Baxalta Reports Positive Phase 1 Results for BAX 930, Investigatiol Recombint ADAMTS13 to Treat Hereditary Thrombotic Thrombocytopenic Purpura
Mar 24, 2016: U.S. FDA Grants Orphan Drug Desigtion to Anfibatide for Treatment of Thrombotic Thrombocytopenic Purpura
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by KM Biologics Co Ltd, 2021
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by Lee’s Pharmaceutical Holdings Ltd, 2021
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by PlateletBio, 2021
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by Sanofi, 2021
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by TagCyx Biotechnologies, 2021
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by Takeda Pharmaceutical Co Ltd, 2021
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by TargED Biopharmaceuticals BV, 2021
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Dormant Projects, 2021
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Discontinued Products, 2021